- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03267901
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome in South Korea
Investigators planed to conduct a randomized, controlled, crossover trial to examine the effects of daily walnuts intake among Korean subjects with metabolic syndrome. Primary objective of this study was to investigate the effects of daily walnut intake on changes of metabolic syndrome indices in Koreans with metabolic syndrome age over 30 years old. This study was consisted of four periods: run-in, first intervention, wash-out, and second intervention phases. As 16 weeks of first intervention period began after the run-in phase, the subjects were randomly assigned into one of two groups: walnut group and control group. Participants in walnut group consumed 45 grams of walnuts on a daily basis and participants in control group were provided iso-caloric white bread for first 16 weeks. After the first intervention and wash-out period (6 weeks), second intervention which is crossover of first intervention was started during the next 16 weeks. Anthropometric measurements and biochemical analyses were done at the beginning and the end of each intervention (0, 16, 22, and 38 weeks of trial). Habitual diet was randomly observed using 3-day diet record once during each phase.
Investigators expected to evaluate 1)effects of walnut ingestion on reverting metabolic syndrome to normal status especially by reducing waist circumference and improving serum levels of triglyceride and high-density lipoprotein, 2)beneficial effects of daily walnut consumption on changes of body composition in the subjects with metabolic syndrome, and 3)regulatory effects of daily walnut intake on inflammatory markers and diabetic markers.
Studieöversikt
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Seoul, Korea, Republiken av, 07327
- ICAN Nutrition Education and Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria: at least three out of five metabolic syndrome components
- waist circumference (WC) >90 cm for men and >80 cm for women
- hypertension (DBP ≥85 and <110 mm Hg)
- hyperglycemia (≥100 mg/dL)
- elevated plasma TG concentrations (≥150 mg/dL)
- decreased plasma HDL-C concentrations (<40 mg/dL for men and <50 mg/dL for women)
Exclusion Criteria:
- the presence of morbid obesity (BMI ≥40)
- the use of any medication for the control of blood pressure, glucose, or lipid metabolism
- a medical history of hypocaloric diet consumption within the past year
- gastrointestinal tract disorders
- post-menopausal women
- smokers
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Walnut-Control
|
45 g of walnut / iso-caloric white bread
|
Experimentell: Control-Walnut
|
45 g of walnut / iso-caloric white bread
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
changes of waist circumference
Tidsram: after 16 weeks of daily walnut consumption
|
Waist circumferences (cm) were obtained at the midpoint between the lowest rib and the iliac crest and rounded to the nearest 0.1 cm after inhalation and exhalation.
|
after 16 weeks of daily walnut consumption
|
changes of blood triglyceride level
Tidsram: after 16 weeks of daily walnut consumption
|
Serum triglycerides (mg/dL) levels were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
changes of blood high-density lipoprotein cholesterol levels
Tidsram: after 16 weeks of daily walnut consumption
|
High density lipoprotein cholesterol (mg/dL) levels were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
changes of blood pressure
Tidsram: after 16 weeks of daily walnut consumption
|
Blood pressure (mmHg) was measured on the right arm using an up-load blood pressure monitor with participants in a comfortably seated position after at least a 5-minute rest.
|
after 16 weeks of daily walnut consumption
|
changes of blood glucose level
Tidsram: after 16 weeks of daily walnut consumption
|
Blood glucose levels (mg/dL) were measured using blood glucose monitor and test stripts from the finger tip.
|
after 16 weeks of daily walnut consumption
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
changes of total cholesterol level
Tidsram: after 16 weeks of daily walnut consumption
|
Serum total cholesterol levels (ml/dL) were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
changes of serum apolipoprotein B level
Tidsram: after 16 weeks of daily walnut consumption
|
Serum apolipoprotein B (ml/dL) was measured using a turbidimetric immunoassay.
|
after 16 weeks of daily walnut consumption
|
changes of serum adiponectin level
Tidsram: after 16 weeks of daily walnut consumption
|
Blood adiponectin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
changes of serum leptin level
Tidsram: after 16 weeks of daily walnut consumption
|
Blood leptin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
changes of serum insulin level
Tidsram: after 16 weeks of daily walnut consumption
|
Serum insulin (μU/mL) was measured with a commercially available kit, the ultrasensitive insulin ELISA kit using an Epoch microplate spectrophotometer.
|
after 16 weeks of daily walnut consumption
|
changes of low-density lipoprotein cholesterol level
Tidsram: after 16 weeks of daily walnut consumption
|
Low-density lipoprotein cholesterol levels (ml/dL) were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CWC-2016-MetS
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metaboliskt syndrom
-
Grand Valley State UniversityAnmälan via inbjudanMetabolic Associated-dysfunction Steatotic Lever Disease (MASLD) | Metabolic Associated-dysfunction Steatohepatit (MASH)Förenta staterna
-
Scripps Whittier Diabetes InstituteAvslutadCardio-metabolic Care-Team Intervention (CMC-TI)
-
Shanghai General Hospital, Shanghai Jiao Tong University...Har inte rekryterat ännuPrediabetes | Kontinuerlig glukosövervakning | Metabolic Management Center
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
TJ Biopharma Co., Ltd.Rekrytering
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RekryteringMyelodysplastiska syndrom (MDS)Förenta staterna, Israel
-
AbbVieCelgene; Genentech, Inc.AvslutadMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Tyskland
-
AbbVieGenentech, Inc.Aktiv, inte rekryterandeMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Kanada, Frankrike, Tyskland, Italien, Storbritannien
Kliniska prövningar på food
-
South Dakota State UniversityUniversity of Missouri-Columbia; Ohio State University; Michigan State University och andra samarbetspartnersAvslutadMatsäkerhet | Näringsvärde
-
International Centre for Diarrhoeal Disease Research...Washington University School of MedicineOkändNäring | Mikrobiota | Kompletterande matBangladesh
-
The Miriam HospitalNational Institute of General Medical Sciences (NIGMS)AvslutadInflammation | Mat osäkerhet | Fetma, barndom | Mental hälsaFörenta staterna
-
Rutgers, The State University of New JerseyRekryteringMiljöexponering | Mat urvalFörenta staterna
-
Ohio State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekryteringDiabetes mellitus, typ 2 | Dålig näring | MatbristFörenta staterna
-
University of British ColumbiaAvslutad
-
NYU Langone HealthAmerican Heart AssociationRekrytering
-
Medical University of South CarolinaWW InternationalAvslutadFetma | ViktminskningFörenta staterna
-
Virginia Polytechnic Institute and State UniversityRekrytering
-
International Centre for Diarrhoeal Disease Research...Washington University School of MedicineRekrytering